APEPTICO - Innovation in peptide drugs
SOLNATIDE: Read the most exciting news related to the exploration of safety, tolerability and clinical efficacy of SOLNATIDE IMP in patients infected with the 2019 new Coronavirus (SARS-CoV-2)
After preparing the Horizon 2020 Grant and Consortium Agreements in record time due to the urgent situation caused by the Corona pandemic, we now have kicked-off the SOLNATIDE project.
The Scientific Coordinator and initiator of the project Prof. Dr. Bernhard Fischer is CEO of the Viennese biotechnology company APEPTICO Forschung und Entwicklung GmbH which is proprietary owner of the medicinal product Solnatide IMP.
As coordinator, RTDS is responsible for the overall project coordination, as well as project management and communication.
The SOLNATIDE project in a nutshell
Funding: €1.626 million
Funding: European Commission (EC) call “H2020-SC1-PHE-CORONAVIRUS-2020” (grant no. 101003595)Project start: April 1st 2020
Duration: 21 months
Consortium: 5 partners from Austria, Germany, Italy and Spain (in alphabetic order)
- APEPTICO Forschung und Entwicklung GmbH, Austria. Scientific coordinator.
- BCN Peptides SA, Spain.
- Ludwig-Maximilians-University Munich (LMU) University Hospital, Germany.
- OPIS SRL, Italy.
- RTDS Association, Austria. RTDS Association is responsible for the overall project coordination, as well as project management and communication.
This project has received funding from the EC special H2020 program “Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic (call )) under the grant no. 101003595.
Peptid-Wirkstoff gegen COVID-19: EU fördert klinische Studie an schwer COVID-19-Erkrankten am Klinikum der Universität München
Peptide agent against COVID-19: EU funding for clinical trial in severe COVID-19 patients at the clinic of LMU Munich
PRESS RELEASE: New therapeutic peptide solnatide to reduce and alleviate intensive care time for COVID-19 patients
Vienna, Austria – 19.01.2021
Finding effective treatment measures for COVID-19 patients is as important as developing vaccines to prevent the spread of the virus which has already claimed the lives of over 2 million people globally. Austrian biotech company APEPTICO, together with four partners, received EU H2020 funding to develop and test an innovative peptide-based drug called solnatide to treat lung conditions resulting from COVID-19. Three clinical studies have proven the beneficial effects and safety of solnatide in treating respiratory conditions previous to COVID-19 and the H2020 SOLNATIDE project finances trials with COVID-19 patients.
European Innovation Council highlights the APEPTICO story "EU-funded company APEPTICO develops treatment for late-stage COVID-19 patients" https://community-smei.easme-web.eu/articles/stories-eu-funded-company-apeptico-develops-treatment-late-stage-covid-19-patients
APEPTICO and the Solnatide H2020 Team took part in the ePitching to Procurers on COVID-19 initiated by the European Innovation Council.
Family Photo of the ePitching community
On November 17th 2020, the solnatide H2020 project and APEPTICO have been selected and invited by the European Innovation Council to present its SOLNATIDE project in front of Procurers from the health-sector from all European countries.
The session was dedicated to connecting public and private procurers, from Europe or anywhere in the world, from the health sector with EIC-funded companies providing medical supply solutions and innovative biotechnologies in response to the COVID-19 pandemic.
The event gathered over 50 public and private procurers, and more than 20 EIC-backed SMEs.
Following the ePitching,
the solnatide project has been named as winner of the presentation event.
Schritt für Schritt gegen COVID-19
Please see the video made by the European Commission for facebook:
Now more than ever, it’s crucial for people to feel that we are stronger together. The European Union and its member states are collectively mobilising over €3 trillion to help save lives, jobs, and businesses, by supporting the thousands of people working together to make a difference.
It’s not in division that we move forward, it’s in togetherness: with the researchers, medical staff, scientists, teachers, friends, and neighbours
behind the scenes.Discover European stories of solidarity and hope that encourage all of us to stand strong.
APEPTICO Forschung und Entwicklung GmbH has signed the
MANIFESTO FOR EU COVID-19 RESEARCH
to maximise the accessibility of research results in the fight against COVID-10
APEPTICO’s global survey on incidence of ARDS and outcomes in hospitalized patients with COVID-19 has been published by Critical Care
Vienna, Austria, 24nd August, 2020: APEPTICO Forschung und Entwicklung GmbH today announced that its global survey on incidence of ARDS and outcomes in hospitalized patients with COVID-19 has been published by Critical Care.
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared just over 7 months ago in Wuhan, China. Early reports indicated that although some cases are asymptomatic, 20% of COVID-19 cases follow a severe course, necessitating hospitalization, with a quarter of hospitalized patients requiring intensive care unit (ICU) facilities. Later reports substantiated these data, although ICU admission rates, proportion of patients receiving invasive mechanical ventilation (IMV), and mortality rates differ considerably between studies.
Acute respiratory distress syndrome (ARDS) is a frequent and life-threatening complication in COVID-19. Patients with moderate-to severe ARDS require invasive mechanical ventilation (IMV) and have a poor prognosis.
APEPTICO’s global survey resulted that among hospitalized COVID-19 patients, approximately 1/3 (33%) develop ARDS, 1/4 (26%) require transfer to an ICU, 1/6 (16%) receive IMV, and 1/6 (16%) die. For COVID-19 patients transferred to an ICU, nearly 2/3 (63%) receive IMV and 3/4 (75%) have ARDS. The mortality rate of ICU COVID-19 patients is 40% and of those who receive IMV 59%; the mortality rate in COVID-19-associated ARDS is 45%, and the incidence of ARDS among non-survivors of COVID-19 is 90%, despite increasing use of anti-viral therapies.
This study received funding support from the European Commission (EC), Grant No. 101003595 and from the Austrian Research Promotion Agency (FFG), Grant No.880862.